Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Steadysingle sourceOne outlet reported this, in 2 reports over 1 day - no second voice in this corpus.
Fri, 28 August 2026Sat, 12 September 2026
What it is about
Julie KimAnn HematolChristopher OreillyKapila VigesTsuyoshi TadaExchange CommissionTakeda Pharmaceutical Company Limited TakedaResearch FoundationTakeda PharmaceuticalsUnited StatesDrug AdministrationDepartment Of Hematology At Moffitt Cancer CenterJapanesePhiladelphia, Pennsylvania, United StatesOsaka, Osaka, JapanJapanPeyman KargarRigaku CorporationRigaku HoldingsHarvest Portfolios Group Inc
Who published it, and when
original reportfirst to report
owensoundsuntimes.com
28 Aug, 22:45over 15 days12 Sept, 19:29
How it spread - 2 original reports
Fri, 28 August 2026
1 report- owensoundsuntimes.com22:45first to report
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera
Sat, 12 September 2026
1 report- owensoundsuntimes.com19:29
Owen Sound Sun-Times brings you Owen Sound business news, stories and PR from Canadian and international businesses.